Diffusion Pharmaceuticals announced that the FDA has granted trans sodium crocetinate (TSC) an orphan drug designation for the treatment of primary brain cancer, glioblastoma multiforme (GBM). TSC is in initiation of Phase 1/2 clinical trial to test for safety and effectiveness in patients newly diagnosed with GBM. TSC is believed to make treatment-resistant tumor cells up to three times more susceptible to standard radiation and chemotherapy treatment by enhancing oxygen diffusion into the tumor micro-environment.

TSC is a novel small molecule for the treatment of hypoxia at the cellular level by enhancing oxygen diffusion selectively to oxygen-deprived tissues. It creates more hydrogen bonds among water molecules that make up the bulk of blood plasma to reduce resistance and enable a faster rate of oxygen diffusion through the plasma. 

For more information call (434) 220-0718 or visit www.diffusionpharma.com.